TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00793819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin
Description: α1-adrenergic antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: silodosin
Description: α1-adrenergic antagonist
Study: NCT02390115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic tape application in shoulder

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Elastic tape application in shoulder
Study: NCT03009513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin+Glimepiride
Study: NCT01420718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
Study: NCT04221126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALA cream
Description: ALA compounded in a cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA cream
Description: ALA compounded in a cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALA gel
Description: ALA compounded in a gel
Study: NCT04004533

Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
Study: NCT05394584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
Study: NCT02506296

Intervention type: DRUG
Group type: OTHER
Intervention: DPPIV inhibitor -
Description: Mixed Meal Tolerance Test with or without a DPPIV inhibitor

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring system.
Description: participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
Study: NCT01887249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study: NCT01420718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iRoot BP
Description: Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
Study: NCT01494246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic mail
Description: Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
Study: NCT04221126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA gel
Description: ALA compounded in a gel
Study: NCT04503356

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI as a standalone procedure
Description: It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI combined with cataract surgery
Description: Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
Study: NCT00947596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine sulfate
Description: dry powder for inhalation
Study: NCT01887249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Study: NCT04330911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
Study: NCT01887249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Study: NCT01694576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and nedaplatin
Description: Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
Study: NCT03698513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: BMS-986177 capsule
Study: NCT00947596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine sulfate
Description: intramuscular injection
Study: NCT02931383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Study: NCT04372849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human nasal insulin
Description: single dose of 160 U of human insulin as nasal spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo solution as nasal spray
Study: NCT03547726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Rehab
Description: These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
Study: NCT02429375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat Plus Brentuximab Vedotin
Description: All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
Study: NCT03544814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib combined with pemetrexed plus cisplatin
Description: Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
Study: NCT03698513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: BMS-986177 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: BMS-986177 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: BMS-986177 capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for BMS-986177)
Description: BMS-986177 placebo match capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for BMS-986177)
Description: BMS-986177 placebo match capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for BMS-986177)
Description: BMS-986177 placebo match capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin tablet
Study: NCT03544814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first icotinib and then pemetrexed plus cisplatin
Description: Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
Study: NCT03475134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIL
Description: Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
Study: NCT03698513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin tablet
Study: NCT03314441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
Study: NCT02671695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine in a dose of 5 mg/day orally for 3 months
Study: NCT01072539

Intervention type: DRUG
Intervention: tigecycline
Description: As prescribed by physician in usual clinical practice
Study: NCT02731118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: AF-enriched egg yolk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: AF-enriched egg yolk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: egg yolk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: egg yolk
Study: NCT00999856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
Study: NCT01597960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
Study: NCT00999856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
Study: NCT00123916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
Study: NCT03316794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-005
Description: intravenous
Study: NCT00533013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Management of heart failure is provided by primary practitioners and consultant cardiologists
Study: NCT00123916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
Study: NCT00533013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease Management and Tele-Monitoring
Description: Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
Study: NCT02545751

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
Study: NCT03514251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The suture marks the location of the parathyroid gland
Description: When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
Study: NCT03829917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine and Paromomycin
Description: 28 days of miltefosine plus 28 days of Paromomycin cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: miltefosine
Description: 28 days of miltefosine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paromomycin
Description: 28 days of paromomycin creaam
Study: NCT01563991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal fluid volume
Description: Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced fluid volume
Description: Subject receives 80 cc/ hr LR during the peri-operative period
Study: NCT00316316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing plus exposure and response prevention (MI plus EX/RP)
Description: Participants will receive 18 sessions of MI plus EX/RP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and response prevention (EX/RP)
Description: Participants will receive 18 sessions of EX/RP.
Study: NCT00564967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT via the Internet
Description: 15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group therapy
Description: 15 weeks, 1 session/week, (2,5 hours.)
Study: NCT03861546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle Shared Medical Appointment (SMA) program
Description: Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
Study: NCT02497157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (L-OHP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride hydrate (CPT-11)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of fluorouracil (CIV 5-FU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate calcium (l-LV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bmab)
Study: NCT03930823

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: One to one interview
Study: NCT00540202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: Tablets taken twice daily for 3 days according to weight based guidelines.
Study: NCT03519620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SWWSV
Description: Behaviours to prevent child obesity
Study: NCT02000479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Study: NCT03475134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
Study: NCT00540202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral quinine
Description: Quinine tablets given at 10mg/kg 8 hourly for 7 days
Study: NCT02572219

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical compound

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02871999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Study: NCT00244855

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: Given IV

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01787240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01640678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReCell epidermal cell suspension grafting
Description: According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser abrasion + UV-therapy
Description: According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
Study: NCT03802266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation guided transthoracic needle aspiration
Description: Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided Transthoracic Needle Aspiration
Description: Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
Study: NCT01713530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.